AMAG Pharmaceuticals, Inc. (AMAG) is presently priced at $12.16 after the most recent trading session. At the very opening of the session, the stock started at $11.67 and reached a high price of $12.25 prior to closing the session at the time the stock reached the value of $11.99. The stock touched a low price of $11.57.
AMAG Pharmaceuticals, Inc. had a pretty Dodgy run when it comes to market performance. The 1-year high price for the company’s stock is recorded at $25.83 on 08/24/18, with the lowest value set at $6.81 for the same time period, on 08/07/19.
AMAG Pharmaceuticals, Inc. (AMAG) full year performance of -52.03% was frailer than previous 6-months performance of -23.57%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, AMAG Pharmaceuticals, Inc. shares are recording -52.91% during the 52-week period from to high price, and 78.56% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $6.81 and $25.83.
The company’s shares, operating in the sector of healthcare managed to top a trading volume set approximately around 2.9 million for the day, which was evidently higher when compared to average daily volumes of the shares.
When it comes to year-to-date metrics, the company recorded performance in the market by -19.95%, having the revenues showcasing 6.76% on a quarterly basis in comparison for the same period the last year. At the time of this writing, the total market value of the company is set at 411.09M, with the company presently having 467 employees.
For the existing quarter market Experts are unanimity agreed that the stock is 2.88
Based on the history of market performance as well as a current state of the stock in the market for AMAG Pharmaceuticals, Inc., analysts are setting an average rating at 2.88. The average rating is provided based on consensus of polled analysts, That is how 0 analysts consider that the company should have BUY rating, 1 rated the stock as an OUTPERFORM, 7 have recommended a HOLD rating, 0 believe that the stock should be rated as UNDERPERFORM and 0 believe that investors should pay attention to SELL rating.
According to data provided from Barchart.com, the moving average for the company in the 100-day period was set at 10.43, with a change in the price noted at unch. In a similar fashion, AMAG Pharmaceuticals, Inc. recorded a movement unchanged for the period of the last 100 days, recording 968,162 in trading volumes.
The 200-day Simple Moving Average (SMA-200) is fairly important for the stock’s performance, with the value standing at -9.20% concluded with the date of this writing. The revenue for the company during the period of the last year (12-month TTM) including active operations recorded 432.40M, additionally marking net income of -$233.30M for the same period
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metric that describes the debt the company is using in order to support assets, correlating with the value of shareholders’ equity. The total Debt to Equity ratio for AMAG is recording 0.54 concluded with the time of this writing. In addition, long term Debt to Equity ratio is set at 0.54.
Information on technical analysis for AMAG Pharmaceuticals, Inc. in the period of the last 50 days includes Raw Stochastic average, set at 96.76%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 96.76%. In the time frame including the last 20 days, the company’s Stochastic %K was 94.29% and its Stochastic %D was recorded at 93.10%.
Taking into consideration the past performance of AMAG Pharmaceuticals, Inc., multiple moving trends are noted. Price performance for year-to-date for the company’s stock appears to be encouraging, given the fact the metric is recording -19.95%. Additionally, trading for the stock in the period of the last six months notably deteriorated to -23.57%, alongside a downfall of -52.03% for the period of the last 12 months. The shares increased approximately by 31.51% in the 7-day charts and went up by 37.56% in the period of the last 30 days. Common stock shares were driven by 6.76% for the lastly recorded quarter.